Thereby, this article summarizes how the clinical employment of Tmab has helped to improve the outcome of patients who suffer from HER2+ breast cancer, as well as the molecular mechanisms that could be behind its antineoplastic activity. The gene discussed is ERBB2; the disease is breast carcinoma.